Therapeutic Efficacy of Melatonin in Patients with Coronavirus 2019: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  • Kamran Bagheri Lankarani Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
  • Maryam Akbari Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
  • Reza Homayounfar National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Reza Tabrizi Noncommunicable Diseases Research Center, Fasa University of Medical Science, Fasa, Iran; Clinical Research Development Unit, Fasa University of Medical Science, Fasa, Iran; USERN Office, Fasa University of Medical Sciences, Fasa, Iran
  • Mohebat Vali Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mohamad- Reza Zakeri Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mojtaba Farjam Noncommunicable Diseases Research Center, Fasa University of Medical Science, Fasa, Iran
  • Mahmoud Khodadost Department of Public Health, School of Health, Larestan University of Medical Sciences, Larestan, Iran
  • Fariba Ahmadizar Department of Data Science and Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands
Keywords: Coronavirus 2019, Melatonin, Mortality, C-reactive Protein

Abstract

The efficacy of melatonin in the treatment of patients with coronavirus 2019 (COVID-19) is controversial. This review has summarized the evidence on the efficacy of oral melatonin compared to placebo in patients with mild to moderate COVID-19 infection. We searched four international online databases and all randomized clinical trials (RCTs) that investigated the effects of melatonin compared with the placebo on clinical outcomes, including mortality, discharge time, O2 saturation (SaO2), and c-reactive protein (CRP) levels in patients with COVID-19 infection, were included. The standard random-effects model with hybrid continuity correction was used to pool the risk ratio (RR), weighted mean difference (WMD), and the I2 index to assess the heterogeneity. A total of 272 patients from five RCTs were included. Our meta-analysis showed melatonin compared to placebo, decreased discharge time (WMD=-0.93 days; 95% confidence interval [CI]:-2.94 to 1.07, P=0.36; I2=56.78%) and the risk of mortality (RR=0.72; 95% CI:0.25 to 2.13, P=0.56; I2=0.0%) in COVID-19 patients. Melatonin intake compared to placebo significantly increased SaO2 (WMD=1.38%; 95% CI:0.09 to 2.68, P=0.04; I2=49.82%) and decreased the CRP levels (WMD=-7.24 mg/l; 95% CI:-11.28 to -3.21, P<0.001) in a sensitivity analysis. Our findings showed the efficacy of melatonin compared to placebo in patients with mild to moderate COVID-19 infection.

References

Merad M, Martin JC. Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(7):448.

https://doi.org/10.1038/s41577-020-0353-y

PMid:32488203 PMCid:PMC7265161

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19):a review. JAMA. 2020;324(8):782-93.

https://doi.org/10.1001/jama.2020.12839

PMid:32648899

Im H, Ammit AJ. The NLRP 3 inflammasome: role in airway inflammation. Clin Exp Allergy. 2014;44(2):160-72.

https://doi.org/10.1111/cea.12206

PMid:24118105

Lin L, Xu L, Lv W, Han L, Xiang Y, Fu L, et al. An NLRP3 inflammasome-triggered cytokine storm contributes to Streptococcal toxic shock-like syndrome (STSLS). PLoS Pathog. 2019;15(6):e1007795.

https://doi.org/10.1371/journal.ppat.1007795

PMid:31170267 PMCid:PMC6553798

Danielski LG, Della Giustina A, Bonfante S, Barichello T, Petronilho F. The NLRP3 inflammasome and its role in sepsis development. Inflammation. 2020;43(1):24-31.

https://doi.org/10.1007/s10753-019-01124-9

PMid:31741197

Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017;34:10-22.

https://doi.org/10.1016/j.smrv.2016.06.005

PMid:28648359

Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583.

https://doi.org/10.1016/j.lfs.2020.117583

PMid:32217117 PMCid:PMC7102583

Juybari KB, Pourhanifeh MH, Hosseinzadeh A, Hemati K, Mehrzadi S. Melatonin potentials against viral infections including COVID-19:Current evidence and new findings. Virus Res. 2020;287:198108.

https://doi.org/10.1016/j.virusres.2020.198108

PMid:32768490 PMCid:PMC7405774

Öztürk G, Akbulut KG, Güney Ş. Melatonin, aging, and COVID-19:Could melatonin be beneficial for COVID-19 treatment in the elderly? Turk J Med Sci. 2020;50(6):1504-12.

https://doi.org/10.3906/sag-2005-356

PMid:32777902 PMCid:PMC7605095

El-Missiry MA, El-Missiry ZMA, Othman AI. Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19. Eur J Pharmacol. 2020;882:173329.

https://doi.org/10.1016/j.ejphar.2020.173329

PMid:32615182 PMCid:PMC7324339

Essa MM, Hamdan H, Chidambaram SB, Al-Balushi B, Guillemin GJ, Ojcius DM, Qoronfleh MW. Possible role of tryptophan and melatonin in COVID-19. Int J Tryptophan Res. 2020;13:1178646920951832.

https://doi.org/10.1177/1178646920951832

PMid:32913393 PMCid:PMC7443751

Feitosa EL, Júnior FTDSS, Nery Neto JAO, Matos LFL, Moura MHS, Rosales TO, De Freitas GBL. COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor. Int J Med Sci. 2020;17(14):2133-46.

https://doi.org/10.7150/ijms.48053

PMid:32922174 PMCid:PMC7484667

Kow CS, Hasan SS. Could melatonin be used in COVID-19 patients with laryngopharyngeal reflux disease? J Med Virol. 2020;93(1):92-3.

https://doi.org/10.1002/jmv.26150

PMid:32519764 PMCid:PMC7300529

NaveenKumar SK, Hemshekhar M, Jagadish S, Manikanta K, Vishalakshi GJ, Kemparaju K, Girish KS. Melatonin restores neutrophil functions and prevents apoptosis amid dysfunctional glutathione redox system. J Pineal Res. 2020;69(3):e12676.

https://doi.org/10.1111/jpi.12676

PMid:32597503

Reiter RJ, Sharma R, Ma Q, Dominquez-Rodriguez A, Marik PE, Abreu-Gonzalez P. Melatonin Inhibits COVID-19-induced Cytokine Storm by Reversing Aerobic Glycolysis in Immune Cells: A Mechanistic Analysis. Med Drug Discov. 2020;6:100044.

https://doi.org/10.1016/j.medidd.2020.100044

PMid:32395713 PMCid:PMC7211589

Salles C. Correspondence COVID-19:Melatonin as a potential adjuvant treatment. Life Sci. 2020;253:117716.

https://doi.org/10.1016/j.lfs.2020.117716

PMid:32334009 PMCid:PMC7195414

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Moher D. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103-12.

https://doi.org/10.1016/j.jclinepi.2021.03.001

https://doi.org/10.1016/j.jclinepi.2021.02.003

PMid:33577987

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

https://doi.org/10.1136/bmj.d5928

PMid:22008217 PMCid:PMC3196245

Wei JJ, Lin EX, Shi JD, Yang K, Hu ZL, Zeng XT, Tong TJ. Meta-analysis with zero-event studies: a comparative study with application to COVID-19 data. Mil Med Res. 2021;8(1):41.

https://doi.org/10.1186/s40779-021-00331-6

https://doi.org/10.21203/rs.3.rs-365606/v1

PMid:34217371 PMCid:PMC8254431

Farnoosh G, Akbariqomi M, Badri T, Bagheri M, Izadi M, Saeedi-Boroujeni A, et al. Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial. Arch Med Res. 2022;53(1):79-85.

https://doi.org/10.1016/j.arcmed.2021.06.006

PMid:34229896 PMCid:PMC8220995

Alizadeh Z, Keyhanian N, Ghaderkhani S, Dashti-Khavidaki S, Shokouhi Shoormasti R, Pourpak Z. A Pilot Study on Controlling Coronavirus Disease 2019 (COVID-19) Inflammation Using Melatonin Supplement. Iran J Allergy Asthma Immunol. 2021;20(4):494-9.

https://doi.org/10.18502/ijaai.v20i4.6959

PMid:34418903

Darban M, Malek F, Memarian M, Gohari A, Kiani A, Emadi A, et al. Efficacy of High Dose Vitamin C, Melatonin and Zinc in Iranian Patients with Acute Respiratory Syndrome due to Coronavirus Infection: A Pilot Randomized Trial. J Cell Mol Anesth. 2020;6(2):164-7.

Mousavi SA, Heydari K, Mehravaran H, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Shamshirian A. Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial. J Med Virol. 2022;94(1):263-71.

https://doi.org/10.1002/jmv.27312

PMid:34460132 PMCid:PMC8662261

Davoodian N, Sharifimood F, Salarbashi D, Elyasi S, Baniasad A, Soltani Bejestani F. The Effect of Melatonin as an Adjuvant Therapy on COVID-19: A Randomized Clinical Trial. 2021. Available from: https://ssrn.com/abstract=3878090.

https://doi.org/10.2139/ssrn.3878090

Li Y, Li S, Zhou Y, Meng X, Zhang JJ, Xu DP, Li HB. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017;8(24):39896-921.

https://doi.org/10.18632/oncotarget.16379

PMid:28415828 PMCid:PMC5503661

Huang SH, Liao CL, Chen SJ, Shi LG, Lin L, Chen YW, et al. melatonin possesses an anti-influenza potential through its immune modulatory effect. J Funct Foods. 2019;58:189-98.

https://doi.org/10.1016/j.jff.2019.04.062

Biancatelli RMLC, Berrill M, Mohammed YH, Marik PE. Melatonin for the treatment of sepsis:the scientific rationale. J Thorac Dis. 2020;12(Suppl 1):S54-65.

https://doi.org/10.21037/jtd.2019.12.85

PMid:32148926 PMCid:PMC7024751

Kleszczyński K, Slominski AT, Steinbrink K, Reiter RJ. Clinical trials for use of melatonin to fight against COVID-19 are urgently needed. Nutrients. 2020;12(9):2561.

https://doi.org/10.3390/nu12092561

PMid:32847033 PMCid:PMC7551551

Anderson G, Reiter RJ. Melatonin:roles in influenza, Covid‐19, and other viral infections. Rev Med Virol. 2020;30(3):e2109.

https://doi.org/10.1002/rmv.2109

PMid:32314850 PMCid:PMC7235470

Shneider A, Kudriavtsev A, Vakhrusheva A. Can melatonin reduce the severity of COVID-19 pandemic? Int Rev Immunol. 2020;39(4):153-62.

https://doi.org/10.1080/08830185.2020.1756284

PMid:32347747

Habtemariam S, Daglia M, Sureda A, Selamoglu Z, Gulhan MF, Nabavi SM. Melatonin and Respiratory Diseases: A Review. Curr Top Med Chem. 2017;17(4):467-88.

https://doi.org/10.2174/1568026616666160824120338

PMid:27558675

Ramlall V, Zucker J, Tatonetti N. Melatonin is significantly associated with survival of intubated COVID-19 patients. MedRxiv. 2020.

https://doi.org/10.1101/2020.10.15.20213546

Zinchuk VV, Poluyan IA, Hlutkin SV. Effects of Melatonin on the Oxygen Transport in Blood, Gas Transmitters, and Prooxidant-Antioxidant Balance in the Exercise. Hum Physiol. 2019;45(6):693-700.

https://doi.org/10.1134/S0362119719050219

Zinchuk VV, Firago ME. Participation of melatonin in regulation of blood oxygen-transport function in oxidative stress induced by injection of lipopolisaccharide. Biomed Khim. 2017;63(6):520-6.

https://doi.org/10.18097/PBMC20176306520

PMid:29251613

Manchester LC, Coto-Montes A, Boga JA, Andersen LP, Zhou Z, Galano A, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59(4):403-19.

https://doi.org/10.1111/jpi.12267

PMid:26272235

Hlutkin S, Zinchuk V. Effect of melatonin on the blood oxygen transport during hypothermia and rewarming in rats. Adv Med Sci. 2008;53(2):234.

https://doi.org/10.2478/v10039-008-0035-7

PMid:18930873

Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y,et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.

https://doi.org/10.1016/j.jcv.2020.104370

PMid:32344321 PMCid:PMC7194648

Potempa LA, Rajab IM, Hart PC, Bordon J, Fernandez-Botran R. Insights into the use of C-reactive protein as a diagnostic index of disease severity in COVID-19 infections. Am J Trop Med Hyg. 2020;103(2):561.

https://doi.org/10.4269/ajtmh.20-0473

PMid:32588812 PMCid:PMC7410479

Wichniak A, Kania A, Siemiński M, Cubała WJ. Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders. Int J Mol Sci. 2021;22(16):8623.

https://doi.org/10.3390/ijms22168623

PMid:34445329 PMCid:PMC8395320

Published
2022-12-20
How to Cite
Bagheri Lankarani , K., Akbari , M., Homayounfar, R., Tabrizi , R., Vali , M., Zakeri , M.- R., Farjam, M., Khodadost, M., & Ahmadizar , F. (2022). Therapeutic Efficacy of Melatonin in Patients with Coronavirus 2019: A Systematic Review and Meta-Analysis of Randomized Controlled Trials . Galen Medical Journal, 11, e2562. https://doi.org/10.31661/gmj.v11i.2562
Section
Review Article